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aided by the improved performance and evolving ergonomics
of these devices. The Hydrojet dissector has proven to be of
enormous benefit in open liver resection. It allows precise
parenchymal dissection and clear exposure of even the small-
est vessels and biliary radicles. Its adoption in open surgery
has been somewhat limited, with the established technologies
of CUSA, bipolar electrocautery and ultrasonic technology
enjoying more widespread adoption. In laparoscopic liver
surgery, few centres routinely employ the Hydrojet. Our insti-
tution routinely employs Hydrojet for live donor hepatectomy
and as such we have extensive experience with the device. We
have employed Hydrojet regularly for laparoscopic hepatec-
tomy and describe herein our technique of parenchymal divi-
sion during major hepatectomy, combining the benefits of
the Hydrojet and the Harmonic Scalpel. We demonstrate the
precise parenchymal dissection made possible by the
laparoscopic Hydrojet. We propose that this technique of liver
resection is safe, efficient and precise.
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LO-A.01 LAPAROSCOPIC
HEPATECTOMY SIGNIFICANTLY
SHORTENS THE TIME TO
POSTOPERATIVE CHEMOTHERAPY IN
OBESE PATIENTS UNDERGOING MAJOR
HEPATECTOMIES
S. C. Agle, P. Philips, M. E. Egger, C. R. Scoggins,
K. M. McMasters and R. C. Martin
University Of Louisville, Louisville, KY
Background and Objectives: The multimodality manage-
ment of resectable hepatic malignancies commonly utilizes
chemotherapy either in a pre-operative/post-operative or
post-operative delivery. The benefit of post-operative chemo-
therapy occurs with early initiation, but is commonly delayed
due to procedural related complications. Minimally invasive
surgery in the obese population is known to significantly
reduce complications, length of stay (LOS) and earlier to
return to baseline. The aim of this study was to compare open
versus laparoscopic surgical approaches to major liver resec-
tion in obese patients.
Methods: We performed a single center retrospective
review of 118 consecutive patients with a BMI ≥25, a diag-
nosis of cancer, underwent a major hepatectomy (>3 seg-
ments) from 2007 through 2012 with planned post-operative
chemotherapy.
Results: A matched group of 42 laparoscopic were com-
pared to 76 open cases having equivalent resections based on
tumor location and diagnosis. There were no differences in
the past medical/surgical history, surgical procedure, and
30-day mortality. The open cohort had more blood loss (475
vs 250 ml p = <0.001), longer LOS (Median 6.5 vs 4.0 days,
p = <0.001) and a prolonged time to post-operative chemo-
therapy initiation (37 vs 24 days, p = <0.001). On multivari-
ate analysis laparoscopic resection was found to be an
independent predictor of a shorter LOS and earlier initiation
of postoperative chemotherapy.
Conclusion: The benefits of laparoscopic major
hepatectomies in the obese population included a shorter
length of stay and earlier initiation of chemotherapy com-
pared to the open group. These benefits were seen without
jeopardizing surgical margins or extent of resection with
associated improved outcomes.
LO-A.02 SURVIVAL ANALYSIS OF
PATIENTS WITH STAGE I AND II
HEPATOCELLULAR CARCINOMA
FOLLOWING LIVER
TRANSPLANTATION AND LIVER
RESECTION
R. M. Seshadri, D. J. Niemeyer, R. Z. Swan, D. Sindram,
J. B. Martinie, M. Russo and D. A. Iannitti
Carolinas Medical Center, Charlotte, NORTH CAROLINA
Introduction: Liver transplantation (LT) is a treatment
option in select patients with hepatocellular carcinoma
(HCC). We compared survival in patients with HCC who had
a transplant versus liver resection based on AJCC clinical
stage.
Method: The study is a retrospective analysis from the
Commission on Cancer’s National Cancer Data Base
(NCDB) between the years 1998–2011. 148,882 patients
with liver cancer were identified, of which 126,858 had HCC.
64,227 patients from 1998–2006 had 5-year survival data.
Patients were stratified by AJCC clinical stage I and II, and
resection was compared to LT. The study was limited to stage
I and II patients as most would fit Milan Criteria for trans-
plantation. Kaplan-Meier curves and log rank tests were used
for statistical analysis.
Results: 3,194 HCC patients met the analysis criteria. Mean
age in the LT group and resection group was 56 and 63
respectively. Among stage I HCC, 839 had LT and 823 had a
liver resection. Among stage II HCC, 806 had LT and 726
had liver resection. In the stage I group, median survival for
LT and resection was 127.9 and 54.1 months respectively
(p < 0.0001), and in the stage II group the median survival
was 111.8 and 41.8 months (p < 0.0001). Resection patients
with stage I HCC had a longer median survival than stage II
patients (p = 0.0002), however there was no significant dif-
ference in the LT group.
Conclusion: Liver transplantation offers a survival advan-
tage compared to resection among patients with AJCC clini-
cal stage I and II HCC.
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LO-A.03 VENOUS THROMBOEMBOLIC
PROPHYLAXIS FOLLOWING HEPATIC
RESECTION: PATTERNS OF CARE
AMONG LIVER SURGEONS
M. Weiss, A. Ejaz, G. Spolverato, Y. Kim, K. Hirose,
C. Wolfgang, M. Choti and T. M. Pawlik
Johns Hopkins Hospital, Baltimore, MD
Introduction: Consensus does not exist around the utiliza-
tion of venous thromboembolic(VTE)-prophylaxis for
patients undergoing hepatic resection. We sought to define
what clinical factors impact choice of VTE-prophylaxis
among hepato-pancreato-biliary (HPB) surgeons.
Method: Surgeons who perform liver resections completed
a web-based survey regarding VTE-prophylaxis. Impact of
physician and clinical factors on VTE-prophylaxis was
analyzed.
Results: 204 responses were received (response rate-67%). Most
respondents practiced at an academic center (87%); surgical train-
ing varied: HPB (24%), transplantation (25%), surgical oncology
(33%), combined HPB/transplantation (13%), or no specialty
training (5%). Most respondents (57%) estimated the risk of VTE
at 4–9%. Although 98% of respondents used VTE-prophylaxis,
there was considerable variability: sequential-compression
devices (89%), unfractionated heparin Q12hr (31%), unfractio-
nated heparin Q8hr (30%), and low-molecular weight heparin
(37%). While 88% of respondents noted their use of VTE-
prophylaxis was not impacted by operative indication (benign
vs. malignant), 16% stated that major resection reduced
their likelihood of administering prophylaxis (Figure). Other
factors associated with decreased likelihood of administering
pharmacologic-prophylaxis included:elevatedINR(75%), throm-
bocytopenia (63%), liver insufficiency (58%), and large blood loss
(45%). 47% of respondents routinely waited until ≥POD1 before
initiating pharmacologic-prophylaxis and 35% hold VTE-
prophylaxis until there are no signs of coagulopathy.Aminority of
respondents (14%) said they routinely send patients home on
prophylaxis. Surgical oncology fellowship trained providers were
more likely to wait until ≥POD1 (OR 2.51) as well as hold prophy-
laxis until no signs of coagulopathy (OR 3.92) (both P < 0.05).
Conclusion: There is considerable practice variation regard-
ing VTE prophylaxis among liver surgeons. While the major-
ity of surgeons routinely employ VTE prophylaxis, the
methods, timing and purported contraindications to VTE
prophylaxis differ significantly among liver surgeons.
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LO-A.04 HYPOPHOSPHATEMIA AFTER
MAJOR HEPATECTOMY AND THE RISK
OF POSTOPERATIVE HEPATIC
INSUFFICIENCY AND MORTALITY: AN
ANALYSIS OF 719 PATIENTS
M. H. Squires1, G. C. Dann1, N. L. Lad1, S. B. Fisher1,
B. M. Martin1, D. A. Kooby1, J. M. Sarmiento2,
M. C. Russell1, K. Cardona1, C. A. Staley1 and S. K. Maithel1
1Department Of Surgery, Division Of Surgical Oncology,
Winship Cancer Institute, Emory University, Atlanta, GA;
2Department Of General And Gastrointestinal Surgery,
Emory University, Atlanta, GA
Background: Hypophosphatemia after hepatectomy corre-
lates with extent of liver resected and suggests hepatic regen-
eration. We hypothesized that following major hepatectomy,
absence of hypophosphatemia is associated with poor regen-
eration and increased postoperative hepatic insufficiency
(PHI) and complications.
Methods: Patients who underwent major hepatectomy (≥3
segments), from 2000–2012 at a single institution were iden-
tified. Postoperative serum phosphorus levels were assessed.
Primary outcomes were PHI (peak bilirubin >7 mg/dL),
major (Clavien Grade III-V) complications, and 30- and
90-day mortality. Univariate and multivariate regression
analyses were performed for each endpoint.
Results: Of 749 major hepatectomy cases, 719 patients had
postoperative phosphorus levels available for analysis. PHI and
major complications occurred in 63 (8.8%) and 169 (23.5%)
patients, respectively. 30- and 90-day mortality rates were 4.0%
and 5.4%, respectively. Average phosphorus level on postopera-
tive day (POD) 2 was 2.4 mg/dL; 201 patients (28.0%) had
phosphorus >2.4 on POD2. Patients with POD2 phosphorus >2.4
had a significantly higher incidence of PHI, major complications,
and mortality (Figure). On multivariate analysis, POD 2 phos-
phorus >2.4 remained a significant risk factor for PHI (HR:1.78,
95% CI: 1.02–3.17, p = 0.048), major complications (HR: 1.57,
95% CI: 1.02–2.47, p = 0.049), 30-day mortality (HR: 2.70, 95%
CI: 1.08–6.76, p = 0.034), and 90-day mortality (HR: 2.51, 95%
CI: 1.03–6.15, p = 0.044). Similarly, patients whose phosphorus
level reached nadir after POD3 had a significantly higher inci-
dence of PHI, major complications, and mortality (Table).
Conclusion: Persistently elevated phosphorus levels
>2.4 mg/dL on POD2 and a delayed nadir in phosphorus
beyond POD3 are significantly associated with increased
postoperative hepatic insufficiency, major complications, and
early mortality. Failure to develop hypophosphatemia within
72 hours after major hepatectomy may reflect insufficient
liver remnant regeneration.
LO-A.05 BORDERLINE OPERABILITY IN
HEPATECTOMY PATIENTS IS
ASSOCIATED WITH HIGHER RATES OF
FAILURE TO RESCUE AFTER SEVERE
COMPLICATIONS
C. D. Tzeng1, A. B. Cooper2, S. A. Curley2, J. N. Vauthey2
and T. A. Aloia2
1University Of Kentucky, Lexington, KY; 2UT MD Anderson
Cancer Center, Houston, TX
Introduction: The influence of age and comorbidities on
post-hepatectomy complications is not clear. To address this
knowledge gap, this study analyzed the incidence and risk
factors for post-hepatectomy morbidity/mortality in patients
with “borderline” operability (BL).
Methods: 7,184 elective hepatectomies were identified in
the 2005–10 ACS-NSQIP database. Perioperative variables
were compared for 30-day morbidity/mortality in BL
patients (defined as age ≥ 75, poor performance status, lung
disease, ascites/varices, recent myocardial infarction, stroke,
steroids, weight loss > 10%, and/or sepsis).
Results: 1,720 (23.9%) patients met the BL definition.
Despite non-BL/BL patients undergoing hepatectomies of
similar extent (p > 0.2), BL patients had higher rates of
severe complications (SC, 25.2% vs. 16.2%) and overall
mortality (4.2% vs. 1.4%, p < 0.001). BL patients with any
SC experienced a 16.9% mortality rate (vs. 8.5% in non-BL,
p < 0.001). They frequently experienced multiple SC
(54.5% ≥ 2 SC; 34.9% ≥ 3 SC), and the mortality disparity
was more pronounced with ≥2 and ≥3 SC (26.7% vs. 17.2%;
39.1% vs. 28.8%, p < 0.001). Multivariate analysis identified
the following risk factors for SC in BL patients: anesthesia
score >3 (odds ratio, OR-2.02), diabetes (OR-1.58), smoking
(OR-1.64), albumin < 3.5 g/dL (OR-1.50), intraoperative
transfusion (OR-2.36), operative time >240 min (OR-1.77),
and concurrent procedure (OR-2.81, all p < 0.01). Independ-
ent predictors of mortality included albumin < 3.5 g/dL (OR-
2.92), thrombocytopenia (OR-2.97), and extended/right
hepatectomy (OR-2.16, all p < 0.01).
Conclusion: BL patients are more likely to experience post-
hepatectomy SC. With less physiologic reserve, they are less
able to be clinically rescued. To improve outcomes, surgeons
should preoperatively optimize comorbidities and limit
procedural magnitude, specifically limiting longer, more
complex resections with higher transfusion risk.
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LO-A.06 RENAL FUNCTION AFTER LOW
CENTRAL VENOUS PRESSURE
ASSISTED LIVER RESECTION.
ASSESSMENT OF 2116 CASES
C. Correa-Gallego, A. Berman, S. C. Denis,
V. Arslan-Carlon, T. Kingham, M. I. D’Angelica,
P. J. Allen, Y. Fong, R. P. DeMatteo, W. R. Jarnagin,
J. Melendez and M. Fischer
Memorial Sloan-Kettering Cancer Center, New York, NY
Background: Low central-venous pressure (LCVP) assisted
hepatectomy is associated with decreased blood-loss and
lower transfusion rates. Concern about its impact on renal
function have prevented wide-spread application. We
reviewed the dynamics of renal function after LCVP-assisted
hepatectomy.
Methods: Retrospective analysis of prospective surgical
database. GFR was calculated using the Cockcroft-Gault
equation and its variation recorded over time. RIFLE criteria
were used to define biochemical postoperative acute renal
failure (ARF). (RIFLE: Risk: 25–50% GFR decrease, Injury:
51–75%, Failure: >75%, Loss/End-stage: irreversible failure
>4 weeks). Clinically-relevant ARF was queried from our
postoperative database.
Results: Between 2003–2012, 2116 LCVP assisted
hepatectomies were identified. Median age was 59 yrs (IQR:
50–69), 50% were male, and 53% had ASA ≥3. Median
number of resected segments was 2 (1–4) and median esti-
mated blood-loss was 300 ml (200–600). Morbidity and
90-day mortality were 21% and 2%. Low baseline GFR
(<90 ml/min) was seen in 64% (median 67 ml/min; IQR:
55–79). Biochemically, 16% (329/2116) had evidence of
postoperative ARF (85% Risk, 14% Injury, and 1% Failure),
of which 198 normalized by the time of discharge. Patients
presenting with low baseline GFR were less likely to develop
biochemical ARF: 11% vs 24% (P < .001). Only nine
patients (<1%) had documented clinical evidence of isolated
renal-dysfunction, none requiring dialysis.
Conclusion: Biochemical alterations in GFR are transient in
the vast majority of patients after LCVP hepatectomy, and its
clinical impact is limited. Our data suggest that clinically
relevant renal dysfunction (exclusive of multiple organ
system failure) is an uncommon event in patients undergoing
LCVP liver resection.
LO-A.07 ADJUVANT STEREOTACTIC
BODY RADIATION FOLLOWING
CHEMOEMBOLIZATION IMPROVES
SURVIVAL IN PATIENTS WITH
NON-RESECTABLE HEPATOCELLULAR
CARCINOMA OVER 3 CENTIMETERS
R. Jacob, K. Keene, F. Turley, D. T. Redden, M. K. Bryant,
D. P. Dorn, L. Dover, J. White, S. H. Gray, D. E. Eckhoff
and D. A. DuBay
University of Alabama at Birmingham, Birmingham, AL
Background: The optimal locoregional treatment for non-
resectable hepatocellular carcinoma (HCC) >3 cm is unclear.
Chemoembolization (TACE) is the most common initial
intervention performed, but rarely completely eradicates the
HCC. The purpose of this study is to measure survival in
HCC patients treated with adjuvant stereotactic body radia-
tion (SBRT) following TACE.
Methods: Patients with HCC >3 cm treated with TACE
alone (n = 124) were compared with those treated with
TACE/SBRT (n = 37). Standard survival analysis was
performed.
Results: There were no significant differences between the
2 groups with regard to age, gender, race, or liver disease
etiology. The MELD scores were not different between
groups (TACE: 11.2 ± 4.2 vs. TACE/SBRT: 10.2 ± 3.6,
p = 0.21) nor were measures of sarcopenia (TACE:
10.6 ± 3.4 vs. TACE/SBRT: 11.2 ± 3.8, p = 0.25). The pre-
TACE mean number of tumors (TACE: 2.1 ± 1.6 vs. TACE/
SBRT: 1.8 ± 1.1, p = 0.57), largest tumor size (TACE:
5.8 cm ± 3.0 vs. TACE/SBRT: 6.1 cm ± 2.4, p = 0.09), total
tumor diameter (TACE: 7.7 cm ± 4.9 vs. TACE/SBRT:
7.8 ± 3.3, p = 0.21) and median alpha feto-protein level
(TACE: 19.8 ± 192.1 vs. TACE/SBRT: 32.7 ± 456.0,
p = 0.53) were not significantly different between groups.
Modified response evaluation criteria in solid tumors
(mRECIST), measured after TACE (but before SBRT admin-
istration), were not different between groups (p = 0.69). After
censoring for liver transplantation, the overall survival was
significantly increased in the TACE/SBRT group compared
to the TACE only group (33 vs. 20 months, p = 0.02, Figure).
Conclusion: Adjuvant SBRT following TACE improves
survival in patients with HCC greater than 3 cm.
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LO-A.08 SURGICAL MANAGEMENT
OF HEPATIC HEMANGIOMAS:
AN INTERNATIONAL
MULTI-INSTITUTIONAL EXPERIENCE
J. T. Miura1, A. Li2, R. Schmocker4, S. Nichols5,
D. Sukato7, E. Winslow4, G. Spolverato6, A. Ejaz6,
M. H. Squires3, D. Kooby3, S. Maithel3, J. M. Sarmiento3,
M. Bloomston5, K. K. Christians1, F. M. Johnston1,
S. Tsai1, K. Turaga1, A. Tsung7, T. Pawlik6, M. Wu2 and
T. C. Gamblin1
1Department Of Surgery, Medical College Of Wisconsin,
Milwaukee, WI; 2Eastern Hepatobiliary Surgery Hospital,
The Second Military Medical University, Shanghai,
SHANGHAI; 3Department Of Surgery, Emory University
School Of Medicine, Atlanta, GA; 4Department Of Surgery,
University Of Wisconsin School Of Medicine And Public
Health, Madison, WI; 5Department Of Surgery, The Ohio
State University, Columbus, OH; 6Department Of Surgery,
Johns Hopkins University School Of Medicine, Baltimore,
MD; 7Department Of Surgery, University Of Pittsburgh
School Of Medicine, Pittsburgh, PA
Introduction: Management of hepatic hemangiomas
remains ill defined. We sought to investigate the indications,
surgical management, and outcomes of patients with
hemangiomas.
Methods: A retrospective review from 7 major liver centers
identifying patients who underwent surgery for hepatic
hemangiomas between 1994 and 2013 was performed.
Clinico-pathologic, treatment and perioperative data were
evaluated.
Results: Of 1,899 patients identified, the median age was
45 years (IQR: 39–52) with patients being predominantly
female (69.9%). Majority of hemangiomas were solitary
lesions (54.8%) with a median size of 8 cm (IQR: 6–10).
Surgery was performed for abdominal symptoms (19%),
diagnostic uncertainty (6%), increasing hemangioma size
(31%), and patient preference (44%). Patients undergoing
resection at western centers (W) were more likely to have
symptomatic hemangiomas as compared to the eastern center
(E) (66.4 vs 9.7%, p < 0.01). Surgical resection requiring a
hemihepatectomy or greater was performed on 535 patients
(28.1%). Median length of stay was 13 days (W: 5 vs E: 14
days, p < 0.01). Clavien Grade 3 or higher complications
occurred in 43 patients (2.3%). The 30 day mortality was
0.2% (n = 4) with no additional mortalities at 90 days. Final
pathology revealed 13 patients (1%) harbored a concomitant
malignancy within the resected hemangioma specimen; eight
of the 13 patients underwent surgery secondary to radio-
graphic uncertainty. Of patients with abdominal symptoms at
the time of surgery, 75% reported improvement of symptoms
postoperatively.
Conclusion: Surgery for hemangiomas can be safely per-
formed at high volume institutions. Variable indications for
liver surgery demonstrate a regional difference in approach to
management.
LO-A.09 PREDICTING
TRANSPLANT-ELIGIBLE RECURRENCE
AFTER INITIAL RESECTION OF
HEPATOCELLULAR CANCER
S. Lee, I. Konstantinidis, T. P. Kingham, M. I. DAngelica,
P. J. Allen, Y. Fong, R. P. DeMatteo and W. R. Jarnagin
Memorial Sloan-Kettering Cancer Center, New York, NY
Aim: Initial(IT) and salvage transplantation (ST) are effec-
tive for hepatocellular carcinoma (HCC) within the Milan
criteria (MC). Reliable prediction of post-resection recur-
rence patterns might allow better prioritization of patients for
transplantation. This study analyzes rates of transplantable
recurrence after complete resection of HCC, stratified by
preoperative MC status and histopathologic factors.
Methods: From January 1992 to January 2012, 320 patients
underwent partial hepatectomy with negative margins at
Memorial Sloan-Kettering Cancer Center. Patients were cat-
egorized preoperatively as within- or beyond-MC, as were
recurrences. Clinicopathological and perioperative param-
eters were analyzed to identify prognostic factors to predict
recurrence pattern.
Results: A total of 304 patients were analyzed. After median
follow-up of 37 months, 180 patients (59%) developed recur-
rence. Patients with tumors within-MC had better survival
outcomes than those beyond-MC (p < 0.001). In patients
who developed recurrence, 71(39%) recurred within-MC
and 109 (61%) recurred beyond-MC (Table 1). Of those
beyond-MC before resection, a significant proportion (21%)
recurred within-MC. Conversely, 19% of patients initially
within-Milan recurred beyond-Milan (Figure 1). Age,
gender, previous major/prior liver resection, tumor differen-
tiation and cirrhosis were not significant predictors if recur-
rence was within- or beyond-MC. Significant factors that
determined recurrence within MC included blood loss during
liver resection (p = 0.007), alpha-fetoprotein (<200 ng/ml)
(p = 0.009), tumor size(p = 0.0004), lymphovascular inva-
sion (p = 0.02), microsatellites (p = 0.003) and pre-operative
MC status (p = 0.003) (Table 1).
Conclusion: After curative hepatectomy, a significant pro-
portion of patients initially beyond-MC experience recur-
rence eligible for ST, while a similar proportion of patients
initially within MC are transplant ineligible after recurrence.
Incorporation of histopathologic parameters to the MC status
may allow better identification of patients for IT and ST.
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LO-A.10 SYNCHRONOUS PRIMARY
COLORECTAL CANCER AND LIVER
METASTASIS: IMPACT OF OPERATIVE
APPROACH ON CLINICAL OUTCOMES
AND HOSPITAL COSTS
A. Ejaz, G. Spolverato, E. Semenov, D. Tanner, J. Hundt
and T. M. Pawlik
Johns Hopkins Hopsital, Baltimore, MD
Introduction: Management of patients with colorectal
cancer (CRC) and synchronous colorectal liver metastasis
(sCRLM) remains controversial. We examined the clinical
and economic impact of managing sCRLM with a staged
versus simultaneous approach.
Method: We identified 229 patients treated for sCRLM
between 1990–2012. Clinicopathologic features, peri-
operative outcomes, and total hospital costs(inflation-
adjusted) were collected and analyzed.
Results: 118 (52%) patients underwent a staged approach
while 111 (48%) had a simultaneous CRC and liver opera-
tion. Overall intra-hepatic tumor burden was similar among
patients treated with staged versus simultaneous approach
(largest metastasis: 3.2 cm vs. 1.9 cm; number of metastasis:
2 vs. 2; both P > 0.05). Liver-directed therapy included hepa-
tectomy (73%), ablation alone (3%) or combined resec-
tion + ablation (24%). A major hepatectomy (>3 segments)
was more common with a staged approach (54% vs.
31%;P < 0.001); 43% of patients underwent an extended
hepatic resection(staged, n = 64 vs. simultaneous, n = 35).
There were 68 (30%) patients who had a post-operative com-
plication with no difference in the staged (38%) vs. simulta-
neous (27%) groups (P > 0.05). 90-day mortality was 1.7%
(staged, 1.7% vs. simultaneous, 1.8%; P = 0.94). Median
total length of hospitalization was longer in the staged (12.5
days) versus simultaneous(7.0 days) group (P < 0.001).
Median total hospital costs were also higher among patients
undergoing a staged approach ($57,821) compared with a
simultaneous operation ($27,401) (P < 0.01). Long-term out-
comes were similar(5-year disease-free survival: staged,
39.8% vs. simultaneous, 48.6%; P = 0.61).
Conclusion: Patients with sCRLM managed with either a
staged or simultaneous approach had comparable peri-
operative and long-term outcomes. However, patients treated
with a simultaneous approach spent significantly fewer days
in the hospital and had a median cost savings of $30,420.
When appropriate, the simultaneous approach for sCRLM
should be preferred.
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LO-B.01 PATIENT SELECTION AND THE
VOLUME EFFECT IN PANCREATIC
SURGERY: UNEQUAL BENEFITS?
L. A. Bliss1,3, C. J. Yang1, K. Lagisetty1, Z. Chau2, S. Ng1,
T. S. Kent1, A. J. Moser1, D. W. McFadden3, M. P. Callery1
and J. F. Tseng1
1Beth Israel Deaconess Medical Center, Boston, MA;
2University Of Massachusetts Medical School, Worcester,
MA; 3University Of Connecticut Health Center,
Farmington, CT
Background: The volume effect in pancreatic surgery is
well established. Regionalization to high-volume centers has
been proposed. The effect of volume-based proposals on
practice patterns is unknown.
Methods: Retrospective review of patients undergoing pan-
createctomy in Nationwide Inpatient Sample (NIS) 2004–
2011. Inpatient mortality and complication rates calculated.
Patients stratified by annual center volume (low <5, medium
5–18, high >18) based on prior publication. Multivariable
regression model evaluated predictors of morbidity, mortality
and resection at a high-volume center.
Results: 129,609 patients underwent pancreatectomy.
Crude inpatient mortality rate was 4.3%, decreasing over
2004–2011 (5.2% to 3.1%, p < 0.0001). 36.0% experienced
complications. 65.2% underwent resection at high-volume
centers. In 2004, low-, medium-, and high-volume centers
resected 16.3%, 26.8%, and 56.9% of patients, compared
with 7.65%, 20.7%, and 71.7% in 2011. High-volume centers
had lower mortality (3.2% versus 6.5%, p < 0.0001), fewer
complications (33.0% versus 41.6%, p < 0.0001) and shorter
median length of stay (9 versus 11 days, p < 0.0001).
However, patients at medium- or low-volume centers had
more co-morbidities (40.9% versus 37.2% with Elixhauser
>2, p = 0.0020), lower rates of private insurance (40.0%
versus 43.8%, p = 0.0030) and more non-elective admissions
(30.6% versus 17.8%, p < 0.0001).
Conclusion: Overall, mortality after pancreatectomy con-
tinues to improve. Despite a shift to high-volume hospitals, a
substantial cohort still receives care outside of these centers.
Patients receiving non-high-volume care demonstrate less
favorable comorbidities, insurance, and urgency of opera-
tion. The implications are twofold: already disadvantaged
patients may not benefit from a high-volume effect; and
patients predisposed to do well may contribute to observed
superior outcomes at high-volume centers.
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